The Pathobiology of Follicular Lymphoma

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2023 Jul 30

PMID 37518274

Authors

Joaquim Carreras

Affiliations

Soon will be listed here.

Abstract

Follicular lymphoma is one of the most frequent lymphomas. Histologically, it is characterized by a follicular (nodular) growth pattern of centrocytes and centroblasts; mixed with variable immune microenvironment cells. Clinically, it is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. It is biologically and clinically heterogeneous. In most patients it is indolent, but others have a more aggressive evolution with relapses; and transformation to diffuse large B-cell lymphoma. Tumorigenesis includes an asymptomatic preclinical phase in which premalignant B-lymphocytes with the t(14;18) chromosomal translocation acquire additional genetic alterations in the germinal centers, and clonal evolution occurs, although not all the cells progress to the tumor stage. This manuscript reviews the pathobiology and clinicopathological characteristics of follicular lymphoma. It includes a description of the physiology of the germinal center, the genetic alterations of BCL2 and BCL6, the mutational profile, the immune checkpoint, precision medicine, and highlights in the lymphoma classification. In addition, a comment and review on artificial intelligence and machine (deep) learning are made.

Citing Articles

Highlights: Follicular lymphoma.

Takata K J Clin Exp Hematop. 2023; 63(4):212-213.

PMID: 38148010 PMC: 10861372. DOI: 10.3960/jslrt.23051.

References

Farinha P, Kyle A, Minchinton A, Connors J, Karsan A, Gascoyne R . Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica. 2010; 95(12):2157-60. PMC: 2995576. DOI: 10.3324/haematol.2009.021766. View

Miyoshi H, Sato K, Kabeya Y, Yonezawa S, Nakano H, Takeuchi Y . Deep learning shows the capability of high-level computer-aided diagnosis in malignant lymphoma. Lab Invest. 2020; 100(10):1300-1310. DOI: 10.1038/s41374-020-0442-3. View

Green M . Chromatin modifying gene mutations in follicular lymphoma. Blood. 2017; 131(6):595-604. PMC: 5805487. DOI: 10.1182/blood-2017-08-737361. View

Ghia P, Boussiotis V, Schultze J, Cardoso A, Dorfman D, Gribben J . Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998; 91(1):244-51. View

Schuler F, Hirt C, Dolken G . Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biol. 2003; 13(3):203-9. DOI: 10.1016/s1044-579x(03)00016-6. View

Halldorsdottir A, Fruhwirth M, Deutsch A, Aigelsreiter A, Beham-Schmid C, Agnarsson B . Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma. Leuk Res. 2008; 32(7):1015-21. DOI: 10.1016/j.leukres.2007.11.028. View

Yoshino T, Takata K, Tanaka T, Sato Y, Tari A, Okada H . Recent progress in follicular lymphoma in Japan and characteristics of the duodenal type. Pathol Int. 2018; 68(12):665-676. DOI: 10.1111/pin.12733. View

Taskinen M, Karjalainen-Lindsberg M, Nyman H, Eerola L, Leppa S . A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007; 13(19):5784-9. DOI: 10.1158/1078-0432.CCR-07-0778. View

Blaker Y, Spetalen S, Brodtkorb M, Lingjaerde O, Beiske K, Ostenstad B . The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol. 2016; 175(1):102-14. DOI: 10.1111/bjh.14201. View

10.

Schmidt J, Ramis-Zaldivar J, Bonzheim I, Steinhilber J, Muller I, Haake A . gene mutations are frequently detected in in situ follicular neoplasia. Blood. 2018; 132(25):2687-2690. PMC: 6302496. DOI: 10.1182/blood-2018-03-837039. View

11.

Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F . High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2007; 26(3):440-6. DOI: 10.1200/JCO.2007.12.8298. View

12.

Okosun J, Wolfson R, Wang J, Araf S, Wilkins L, Castellano B . Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2015; 48(2):183-8. PMC: 4731318. DOI: 10.1038/ng.3473. View

13.

Yoshida H, Kiyuna T . Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology. World J Gastroenterol. 2021; 27(21):2818-2833. PMC: 8173389. DOI: 10.3748/wjg.v27.i21.2818. View

14.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

15.

Krysiak K, Gomez F, White B, Matlock M, Miller C, Trani L . Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017; 129(4):473-483. PMC: 5270390. DOI: 10.1182/blood-2016-07-729954. View

16.

Schmidt J, Ramis-Zaldivar J, Nadeu F, Gonzalez-Farre B, Navarro A, Egan C . Mutations of are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood. 2017; 130(3):323-327. PMC: 5520474. DOI: 10.1182/blood-2017-03-776278. View

17.

Tamma R, Ingravallo G, Annese T, Gaudio F, Perrone T, Musto P . Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. J Clin Med. 2022; 11(5). PMC: 8911525. DOI: 10.3390/jcm11051257. View

18.

Eguchi Y, Ewert D, Tsujimoto Y . Isolation and characterization of the chicken bcl-2 gene: expression in a variety of tissues including lymphoid and neuronal organs in adult and embryo. Nucleic Acids Res. 1992; 20(16):4187-92. PMC: 334124. DOI: 10.1093/nar/20.16.4187. View

19.

Ci W, Polo J, Cerchietti L, Shaknovich R, Wang L, Yang S . The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009; 113(22):5536-48. PMC: 2689052. DOI: 10.1182/blood-2008-12-193037. View

20.

Roulland S, Lebailly P, Lecluse Y, Heutte N, Nadel B, Gauduchon P . Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia. 2005; 20(1):158-62. DOI: 10.1038/sj.leu.2404035. View